-+ 0.00%
-+ 0.00%
-+ 0.00%

Reyon Pharmaceutical to Repurchase KRW 770 Million in Debt Before Maturity

PUBT·11/17/2026 08:15:34
Listen to the news
Reyon Pharmaceutical to Repurchase KRW 770 Million in Debt Before Maturity
  • Reyon Pharmaceutical will repurchase KRW 770 million of third-series convertible bonds before maturity on November 17, 2026.
  • The repurchase payment totals KRW 850.45 million, including principal and interest, funded with internal cash.
  • Outstanding principal will fall to KRW 80.18 billion; the bonds mature on October 25, 2029.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Reyon Pharmaceutical Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261117000188), on November 17, 2026, and is solely responsible for the information contained therein.